Company Announcements - 2010
-
AutoStart Burette Recieves FDA 510(k) Clearance9 March 2010Analytica Ltd is pleased to announce receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the AutoStart Burette in the United States. This is a significant milestone in the commercialisation of the AutoStart Burette, opening up one of the world's most significant medical device market.
-
Appendix 3B2 March 2010New issue announcement, application for quotation of additional securities and agreement.
-
Form 6032 March 2010Notice of initial substantial holder
-
Appendix 4D - Half Yearly Report26 February 2010For the 6 months ended December 2009 (current period) and the previous corresponding period 6 months ended 31 December 2008
-
Market Update5 February 2010
Analytica Limited wishes to advise that it’s National Health & Medical Research Council (NHMRC) grant application has been unsuccessful. Analytica, in conjunction with Professor Paul Haber of the University of Sydney, applied for a NHMRC grant to partly fund the early stages of its Naltrexone implant program. Analytica is aiming to produce a TGA-approved Naltrexone implant for the treatment of drug and alcohol addiction. Currently, there is no generally available, TGA-approved implant to treat such addictions.
-
Appendix 4C - Quarterly Cash Flow29 January 2010
Analytica presents its Appendix 4C for the quarter ended 31 December 2009.
-
Appendix 3B22 January 2010
New issue announcement, application for quotation of additional securities and agreement.